小儿实体瘤的综合组学分析及相关生物学研究库的建立
Background:
- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system.
Objectives:
- To collect and store blood, serum, tissue, urine, or tumor samples of children who have cancer or adults who have common childhood cancers.
Eligibility:
- Individuals who have been diagnosed with a common childhood cancer (e.g., leukemia) regardless of patient age.
- Children, adolescents, and adults who have been diagnosed with a type of cancer more commonly found in adults.
Design:
- Extra blood, serum (the liquid part of blood), tissue, urine, or tumor samples will be collected from participants at a time when sampling is required for medical care or as part of a research study.
- No additional procedures will be performed for the sole purpose of obtaining additional tumor tissue, aside from what is required for clinical care.
研究概览
详细说明
Background:
-Laboratory-based investigations have contributed to an improved understanding of the biology of cancer and to the development of new therapies for pediatric malignancies.
Objectives:
-Systematic Molecular, Genomic, Proteomic, Metabolomic ("Omic") and other profiling for enrolled subjects where omics refers to mechanistic studies using a set of advanced technologies to capture comprehensive aspects of biological systems providing insights into structure, function and interactions to understand these complex processes and diseases better.
Eligibility:
Pediatric or Adult subjects of any age with one of the following:
- Diagnosis of any tumor or malignancy, pre-malignant disorder or suspected cancer susceptibility familial syndromes, regardless of age
- Individuals without malignancy undergoing surgery, other treatment such as apheresis or normal well visit or routine blood draw as part of standard of care.
- Biological relatives of a subject with a tumor or malignancy (pediatric or adult) or with suspected familial cancer syndrome. Patients enrolled in an approved companion protocol
- Blood and/or tissue specimens that have been previously collected and are available for research analysis
- Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.
Design:
-
This study will allow for the collection of specimens for a Tissue Repository, and for designated sample investigations including systematic molecular, genomic and proteomic (Omic) profiling, and growth factor and cellular profile investigations.
-
Testing activities may include:
- DNA, RNA and protein extracted from a section of tumor and normal samples; the remainder will be stored.
- Germ line DNA and RNA extracted from lymphocytes or other normal uninvolved tissue
- Germ line DNA will be extracted from lymphocytes or other normal uninvolved tissue of relatives of the subject.
- Xenografts, explant and cell lines established from tumor, pre-malignant and normal samples
- Tumor samples and samples for circulating tumor cells sent for the establishment of Xenografts and single cell suspension of tumor for drug testing or for monitoring cell free DNA over time
- Omics (Genomics and Proteomic) studies will be performed
- Growth factor and cellular profile investigations of bone marrow-derived cell populations to include quantification of hematopoietic progenitor cells (HPCs), endothelial progenitor cells (EPCs), and mesenchymal progenitor cells (MPCs), levels of matrix metalloprotease 2 and 9 (MMP2) and (MMP9), gene expression, growth factor and microvesicle analysis and bone marrow analysis of progenitor cells in blood and tissue.
- Research tests described in active IRB approved protocols.
- Immune profiling and stromal profiling of blood, tumor, and normal tissues
- Immune function studies from blood and normal tumor tissues.
-
Utilizing an oversight committee to oversee the receipt and the distribution of unlinked tissues to other investigators.
-
Qualitative methodologies will be used to ascertain knowledge, attitudes, beliefs, and behaviors in 25-35 parents/caregivers at NIH concerning the anticipated use of NGS for diagnosing and directing therapy for pediatric cancer and how incidental findings might be returned.
-
Expected accrual of 100-150 patients per year.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Donna B Bernstein, R.N.
- 电话号码:(240) 760-6189
- 邮箱:bernsted@mail.nih.gov
研究联系人备份
- 姓名:Rosandra N Kaplan, M.D.
- 电话号码:(240) 760-6198
- 邮箱:kaplanrn@mail.nih.gov
学习地点
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 完全的
- Children's National Medical Center
-
-
Florida
-
Orange、Florida、美国、92613
- 撤销
- Children's Hospital of Orange County (CHOC Children's)
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- 招聘中
- National Institutes of Health Clinical Center
-
接触:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- 电话号码:TTY dial 711 800-411-1222
- 邮箱:ccopr@nih.gov
-
-
New York
-
New York、New York、美国、10029-0574
- 撤销
- Tisch Cancer Institute, Mount Sinai Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、美国、28203
- 撤销
- Carolinas Medical Center/Levine Children's Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Subjects with a diagnosis of any tumor or malignancy regardless of age, or without malignancy undergoing surgery, other treatment or normal well visit. Suspicion of a familial premalignant condition. Biological relatives of a subject with a pediatric or adult tumor or malignancy or with suspected familial cancer syndrome.
描述
- SUBJECT INCLUSION CRITERIA:
Pediatric or adult subjects with one of the following:
- Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;
- Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;
- Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;
- Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.
- Human samples, specimens and data collected on IRB approved protocols that are now closed
- Ability of subject, Legally Authorized Representative (LAR), or parent/legal guardian of children <=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.
Inclusion Criteria for Social and Behavioral Outcome Interviews:
- Parent/caregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.
- Must be able to give consent and sign the informed consent document.
- Able to understand the English language.
EXCLUSION CRITERIA:
None
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:OTHER
队列和干预
团体/队列 |
|---|
|
1/Cohort 1
Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit. |
|
2/Cohort 2
Human samples, specimens and data collected on IRB approved protocols that are now closed |
|
3/Cohort 3
Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
tissue analysis
大体时间:ongoing
|
Perform systematic molecular, genomic, proteomic, metabolomics and other high throughput ( Omics ) profiling on tumor and normal tissues |
ongoing
|
合作者和调查者
调查人员
- 首席研究员:Rosandra N Kaplan, M.D.、National Cancer Institute (NCI)
出版物和有用的链接
一般刊物
- Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8. doi: 10.1093/jnci/91.12.1051.
- Khan J, Bittner ML, Chen Y, Meltzer PS, Trent JM. DNA microarray technology: the anticipated impact on the study of human disease. Biochim Biophys Acta. 1999 Mar 25;1423(2):M17-28. doi: 10.1016/s0304-419x(99)00004-9.
- Khan J, Saal LH, Bittner ML, Chen Y, Trent JM, Meltzer PS. Expression profiling in cancer using cDNA microarrays. Electrophoresis. 1999 Feb;20(2):223-9. doi: 10.1002/(SICI)1522-2683(19990201)20:23.0.CO;2-A.
研究记录日期
研究主要日期
学习开始 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 100086
- 10-C-0086
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
IPD 共享时间框架
Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
IPD 共享访问标准
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. Genomic data are made available via dbGaP through requests to the data custodians.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.